Digital News Report – The US Food and Drug Administration (FDA) announced the approval of Viibryd medication (vilazodone hydrochloride) for treatment of adults diagnosed with major depressive disorder. Viibryd is manufactured by PgxHealth from New Haven, Connecticut.
Symptoms of major depression include having a depressed mood, not being interested in things, gaining or losing weight, change in appetite, insomnia or sleeping too much. Other symptoms also are fatigue, feelings of worthlessness, feeling guilty, slowed thinking, inability to concentrate. A person that have thoughts of suicide or have attempted suicide are also symptoms of major depression.
Viibryd has been approved for doses of 10, 20, and 40 milligrams. The clinical trials side effects most often experienced for Viibryd were diarrhea, nausea, vomiting, and insomnia. There is also a box warning for and increased risk for suicidal behavior and thoughts in children, adolescents, and young adults between the ages of 18 to 24 when treatment begins. This box warning is posted on all antidepressant medication. The FDA points out that adults over 24 did not have this increased risk but instead showed a decreased in suicidal thoughts and behaviors.
By Victoria Brown